

Kolmar BNH sharpens global competitiveness with dual functionality of HemoHIM

24 June 2024 | News

The company secured approval from the Ministry of Food and Drug Safety for the fatigue-improving function of the HemoHIM extract complex of angelica gigas, etc., derived from angelica gigas and other components in 2023



The company secured approval from the Ministry of Food and Drug Safety for the fatigue-improving function of the HemoHIM extract complex of angelica gigas, etc., derived from angelica gigas and other components in 2023

South Korea's Kolmar BNH, a leading Original Development Manufacturing (ODM) company for health-functional foods, strengthens its market position by acquiring certification for the additional functionality of HemoHIM, a renowned Korean health supplement.

The company secured approval from the Ministry of Food and Drug Safety for the fatigue-improving function of the HemoHIM extract complex of angelica gigas, etc., derived from angelica gigas and other components in 2023. This achievement was made six years after the launch of its HemoHIM Sustainable Technology Development Project. As a result, HemoHIM came to the market as a dual-functional health product designed to boost immune function and reduce fatigue.

HemoHIM, developed by Kolmar BNH in 2006, is the nation's first individually-approved immune-boosting health supplement, formulated using indigenous natural ingredients like angelica gigas, cnidium officinale, and paeonia japonica. Distributed by Atomy, it's now a global success, exported to over 20 countries and generating over KRW 2 trillion in sales with exports exceeding \$200 million. It has remained Korea's top-selling immune booster for over a decade.